U.S., April 7 -- ClinicalTrials.gov registry received information related to the study (NCT07512076) titled 'A Dose Optimization Study of Enzalutamide in Elderly Patients With Advanced Prostate Cancer' on March 25.
Brief Summary: This is a phase II, single-centre, pragmatic, non-randomized, dose escalation study to evaluate optimal dose levels of enzalutamide in elderly patients using pharmacokinetic blood sampling concentrations.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Prostate Cancer Patients
Elderly Patients
Pharmacokinetic Study
Intervention:
DRUG: Enzalutamide Dose Escalation
Participants will be allocated to receive one of 4 dose levels of enzalutamide;
* Level 1: 40mg
* Level 2: 80mg
* Level 3: ...